{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:55:27Z","timestamp":1790747727462,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine glycated hemoglobin (HbA1c) thresholds for detecting 2-hour plasma glucose (2hPG)-defined post-load dysglycemia and diabetes-range hyperglycemia, and to assess whether adding fasting plasma glucose (FPG) improves discrimination in Vietnamese women with polyendocrine metabolic ovarian syndrome (PMOS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a secondary diagnostic-accuracy analysis of a prospective cohort of 1,149 women with PMOS seeking fertility care. FPG was measured immediately before glucose administration at the OGTT visit after an overnight fast of at least 8 hours. The reference standard was 2hPG during a 75-g oral glucose tolerance test (OGTT): post-load dysglycemia was defined as 2hPG \u2265140 mg\/dL and diabetes-range 2hPG hyperglycemia was defined as a single 2hPG \u2265200 mg\/dL. Discrimination was assessed using receiver operating characteristic curves, area under the curve (AUC), Youden-optimal thresholds, paired DeLong tests, and bootstrap validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 1,149 women, 342 (29.8%) had 2hPG-defined post-load dysglycemia, including 61 (5.3% of the total cohort) with 2hPG-defined diabetes-range hyperglycemia. HbA1c outperformed FPG for both outcomes (AUC, 0.711 vs 0.634 and 0.799 vs 0.719, respectively). The Youden-optimal HbA1c threshold was 5.58% (37 mmol\/mol) for 2hPG-defined post-load dysglycemia (sensitivity, 53.8%; specificity, 80.5%) and 5.62% (38 mmol\/mol) for 2hPG-defined diabetes-range hyperglycemia (sensitivity, 68.9%; specificity, 80.0%). The Youden-derived cutoffs are exploratory statistical reference points. For the diabetes-range endpoint, an exploratory HbA1c cutoff of 5.3% (34 mmol\/mol) achieved a point-estimate sensitivity of 93.4% and specificity of 34.5%, but would lead to OGTT in 670 per 1,000 women screened. Adding FPG produced small numerical increases in AUC, but there was no statistically significant evidence of improved discrimination over HbA1c alone; bootstrap validation of the combined models showed minimal optimism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among Vietnamese women with PMOS seeking fertility care, HbA1c may help prioritize confirmatory OGTT, but it cannot rule out 2hPG-defined post-load dysglycemia or replace OGTT for definitive glycemic classification. The Youden-derived thresholds should be considered exploratory, and external validation is required before clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1968625","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:34Z","timestamp":1790744194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glycated hemoglobin thresholds for detecting 2-hour plasma glucose-defined abnormal glucose metabolism in Vietnamese women with polyendocrine metabolic ovarian syndrome"],"prefix":"10.3389","volume":"17","author":[{"given":"Nam T.","family":"Nguyen","sequence":"first","affiliation":[{"name":"IVFMD, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]},{"name":"HOPE Research Center, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc D.","family":"Truong","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]},{"name":"HOPE Research Center, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien T. A.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"HOPE Research Center, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]},{"name":"Endocrine Clinic, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toan D.","family":"Pham","sequence":"additional","affiliation":[{"name":"HOPE Research Center, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh H. N.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"HOPE Research Center, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duy L.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"HOPE Research Center, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu N. A.","family":"Ho","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]},{"name":"HOPE Research Center, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuong M.","family":"Ho","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]},{"name":"HOPE Research Center, My Duc Hospital","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan N.","family":"Vuong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy at Ho Chi Minh City","place":["Ho Chi Minh City, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00717-8","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process","volume":"407","author":"Teede","year":"2026","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v13.i3.129","article-title":"Markers of insulin resistance in polycystic ovary syndrome women: An update","volume":"13","author":"Amisi","year":"2022","journal-title":"World J Diabetes"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/diab.38.9.1165","article-title":"Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome","volume":"38","author":"Dunaif","year":"1989","journal-title":"Diabetes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmq001","article-title":"Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"16","author":"Moran","year":"2010","journal-title":"Hum Reprod Update"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmy007","article-title":"Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression","volume":"24","author":"Kakoly","year":"2018","journal-title":"Hum Reprod Update"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoag012","article-title":"Impact of glucose metabolism abnormalities on live birth rate in South-East Asian women with polycystic ovary syndrome","volume":"2026","author":"Nguyen","year":"2026","journal-title":"Hum Reprod Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S002","article-title":"2. Diagnosis and classification of diabetes: Standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060607","article-title":"Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome","volume":"176","author":"Gagnon","year":"2007","journal-title":"CMAJ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.metabol.2019.01.015","article-title":"Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: Fasting plasma glucose or oral glucose tolerance test","volume":"93","author":"Ortiz-Flores","year":"2019","journal-title":"Metabolism"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14982","article-title":"The role of glycated hemoglobin in the diagnosis of prediabetes and diabetes mellitus in young women with polycystic ovary syndrome","volume":"100","author":"Melo","year":"2024","journal-title":"Clin Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/det002","article-title":"Assessment of impaired glucose tolerance prevalence with hemoglobin A1c and oral glucose tolerance test in 252 Turkish women with polycystic ovary syndrome: a prospective, controlled study","volume":"28","author":"Celik","year":"2013","journal-title":"Hum Reprod"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/det255","article-title":"Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method","volume":"28","author":"Lerchbaum","year":"2013","journal-title":"Hum Reprod"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.102970","article-title":"Diagnostic accuracy of oral glucose tolerance tests, fasting plasma glucose and haemoglobin A1c for type 2 diabetes in women with polycystic ovary syndrome: A systematic review and meta-analysis","volume":"18","author":"Belsti","year":"2024","journal-title":"Diabetes Metab Syndrome: Clin Res Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1694","article-title":"A1C cut points to define various glucose intolerance groups in Asian Indians","volume":"33","author":"Mohan","year":"2010","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12419","DOI":"10.1038\/s41598-018-29998-z","article-title":"Screening for diabetes with HbA1c: Test performance of HbA1c compared to fasting plasma glucose among Chinese, Malay and Indian community residents in Singapore","volume":"8","author":"Lim","year":"2018","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril"},{"key":"B19","unstructured":"Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome (PCOS) | NIH Office of Disease Prevention Website\n          \n          \n          \n          2026"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1109\/LSP.2014.2337313","article-title":"Fast implementation of DeLong\u2019s algorithm for comparing the areas under correlated receiver operating characteristic curves","volume":"21","author":"Sun","year":"2014","journal-title":"IEEE Signal Process Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.12.009","article-title":"Sample size calculation should be performed for design accuracy in diagnostic test studies","volume":"58","author":"Flahault","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: A novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2017.12.006","article-title":"Optimal hemoglobin A1C cutoff value for diabetes mellitus and pre-diabetes in Pudong New Area, Shanghai, China","volume":"12","author":"Zhou","year":"2018","journal-title":"Prim Care Diabetes"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1968625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:56:36Z","timestamp":1790744196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1968625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":25,"alternative-id":["10.3389\/fendo.2026.1968625"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1968625","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1968625"}}